HYDAMTIQ
Modify Date: 2024-02-04 10:17:37
HYDAMTIQ structure
|
Common Name | HYDAMTIQ | ||
|---|---|---|---|---|
| CAS Number | 1201832-32-7 | Molecular Weight | 274.34 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C14H14N2O2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of HYDAMTIQHYDAMTIQ is a PARP-1/2 inhibitor (IC50: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more[1]. |
| Name | HYDAMTIQ |
|---|
| Description | HYDAMTIQ is a PARP-1/2 inhibitor (IC50: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more[1]. |
|---|---|
| Related Catalog | |
| Target |
PARP-1/2[1] |
| References |
| Molecular Formula | C14H14N2O2S |
|---|---|
| Molecular Weight | 274.34 |